TP-05: An investigational therapeutic for the prevention of Lyme disease

What is TP-05?

TP-05 is an oral, systemic formulation of lotilaner in development for the prevention of Lyme disease.1

Currently, there is no FDA-approved pharmacological option for preventing Lyme disease.1

TP-05 is1:

Learn more about our efforts to prevent Lyme disease.

Read about the Phase I Callisto Trial
Reference:

1. Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. Tarsus Pharmaceuticals, Inc. Press release. June 16, 2021.

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

Opt-in
This field is for validation purposes and should be left unchanged.